MiNK Therapeutics, Inc.
INKTHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeMiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural. At a $58.4M market cap, MiNK Therapeutics, Inc. ranks as a micro-cap company within healthcare. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Market Cap
$58.4M
Beta
0.49
P/E (TTM)
—
P/E (Fwd)
-4.33
EPS (TTM)
$-2.37
EPS (Fwd)
$-2.65
ROE
—
ROA
-123.8%
Cash
$8.8M
Total Debt
$0
Free CF
-$5.3M
52W Change
-23.9%
Annual Financials
Cash vs Debt
Where INKT stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INKT finished 0.98% above its 150-day moving average ($11.22) and 0.44% below its 200-day moving average ($11.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INKT overbought or oversold?
At the September 3, 2026 close, INKT's RSI(14) was 53.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MiNK Therapeutics, Inc. reports $8.8M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$5.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
With a beta below 0.7, MiNK Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MiNK Therapeutics, Inc. and its sector.